HRHanna Renk

Hanna Renk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hanna Renk has a total of 251 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical recommendations for the inpatient management of lower respiratory tract infections in children and adolescents with severe neurological impairment in Germany—2026 Update

    by Maximilian David Mauritz, Ulrich von Both, Christian Dohna-Schwake, Christian Gille, Johannes Huebner, Markus Hufnagel, Johannes G. Liese, Hanna Renk, Henriette Rudolph, Ulf Schulze-Sturm, et al.

    Children and adolescents with severe neurological impairment (SNI) require specialized care due to their complex medical needs. These patients often experience severe, recurrent lower respiratory tract infections (LRTIs). These infections, of both viral and bacterial etiology, pose a significant risk to these patients, often resulting in respiratory insufficiency and long-term impairments. Based on expert consensus and newly available data, we have updated the previous 2024 clinical recommendations on the management of LRTIs in children and adolescents with SNI in Germany. This update now also addresses multidrug-resistant organism colonization, respiratory support, discharge planning, and prophylactic strategies. The recommendations emphasize comprehensive multidisciplinary care, antimicrobial stewardship, and a stepwise, risk-stratified approach to antibiotic therapy. Initial treatment should involve symptomatic care, including hydration, antipyretics, oxygen therapy, secretion management, and respiratory as well as cough support. In suspected bacterial LRTIs, antibiotic treatment (ABT) should be guided by clinical severity, previous microbiological findings, and treatment response, with an aminopenicillin plus a beta-lactamase inhibitor recommended for community-acquired LRTIs and piperacillin-tazobactam reserved for selected high-risk patients. Ongoing management includes regular reassessment, adjustment of ABT based on pathogen identification, and optimization of supportive care. Conclusion : The updated recommendations provide a practical, multidisciplinary framework for the inpatient management of LRTIs in children and adolescents with SNI, combining optimized supportive care with antimicrobial stewardship and a stepwise, risk-stratified approach to antibiotic treatment. What is Known: • Children and adolescents with severe neurological impairment are particularly affected by severe and recurrent lower respiratory tract infections (LRTI) • The indication and choice of antibiotic therapy for bacterial LRTI is often difficult because there are no evidence-based treatment recommendations for this heterogeneous but vulnerable patient population • The frequent overuse of broad-spectrum or reserve antibiotics in this patient population increases selection pressure for multidrug-resistant pathogens What is New: • Compared with the 2024 recommendations, this update provides more detailed guidance on secretion management and respiratory and cough support, introduces explicit discharge criteria, and expands decision-making for patients colonized with multidrug-resistant organisms. The antibiotic strategy has been further specified regarding broad-spectrum antibiotic therapy, while preventive recommendations have been expanded and updated.

  • Peritonitis Peritonitis

    by Hanna Renk, Markus Dietzel, Johannes Hübner, Jan de Laffolie, Benjamin Schwab-Eckhardt, Arne Simon, Udo Rolle

  • Appendizitis

    by Hanna Renk, Markus Dietzel, Johannes Hübner, Jan de Laffolie, Benjamin Schwab-Eckhardt, Arne Simon, Udo Rolle

  • Perioperative Antibiotikaprophylaxe Antibiotikaprophylaxe perioperative

    by Hanna Renk, Markus Dietzel, Johannes Forster, Fabian Lander, Paolo Paioni, Udo Rolle, Benjamin Schwab-Eckhardt, Reinhard Berner, Ulrich Heininger, Arne Simon

  • Open Access

    Erratum zu: Antibiotische Therapie in der ambulanten Pädiatrie

    by Hanna Renk, Özgür Dogan, Wolfgang Klein, Jennifer Neubert, Roland Tillmann, Johannes Pfeil, Arbeitsgemeinschaft Antibiotic Stewardship in der ambulanten Pädiatrie (ABSaP)

  • Open Access

    Antibiotische Therapie in der ambulanten Pädiatrie

    by Hanna Renk, Özgür Dogan, Wolfgang Klein, Jennifer Neubert, Roland Tillmann, Johannes Pfeil, Arbeitsgemeinschaft Antibiotic Stewardship in der ambulanten Pädiatrie (ABSaP)

    Zusammenfassung: Antibiotika sollten im klinischen Alltag möglichst gezielt und zurückhaltend eingesetzt werden. Die praktische Umsetzung einer rationalen Antibiotikatherapie ist jedoch nicht einfach, und insbesondere in der kinder- und jugendärztlichen Grundversorgung bestehen häufig diagnostische, therapeutische und prognostische Unsicherheiten. Um Verordnungsunsicherheiten zu reduzieren, die Therapie- und Kommunikationsstrategien für eine rationale Antibiotikatherapie anzugleichen und den Bedarf an unmittelbar praxisrelevantem Material zu erfüllen, wurden die Empfehlungen Antibiotische Therapie in der ambulanten Pädiatrie aktualisiert und im März 2024 herausgegeben. In dem aktuellen Artikel werden relevante Literatur und praktische Überlegungen, die die Grundlage der aktualisierten Empfehlungen bilden, dargelegt und diskutiert. Der Hintergrund der aktuellen Empfehlungen soll damit für alle in der ambulanten Kinder- und Jugendmedizin tätigen Personen transparent dargestellt werden.


  • Open Access

    Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed families

    by Alex Dulovic, Armin Rabsteyn, Jonathan Remppis, Irene K. E. Gentzcke, Julia Mueller, Nadja Tuecks, Matthias Becker, Daniel Junker, Philipp D. Kaiser, Bjoern Traenkle, et al.

    Identification of previous SARS-CoV-2 infection typically relies on serology, yet T-cells play a key role in the adaptive immune response against SARS-CoV-2. Here, we investigated in parallel the SARS-CoV-2-specific as well as endemic human coronavirus-specific humoral and cross-reactive cellular responses in children and adults. We analyzed clinical data and blood samples from a family cohort of 96 children and 144 adults at 3–4 and 11–12 months after their first contact with SARS-CoV-2. Humoral response was assessed by a multiplex immunoassay with high sensitivity and specificity (MULTICOV-AB). Cellular responses were analyzed by IFN-γ ELISPOT using four different established epitope compositions (ECs) to discriminate between SARS-CoV-2 specific and HCoV cross-reactive T-cell responses. While the majority of adults had a combined serological and T-cell response, relatively more children had a T-cell response alone rather than a combined response. The magnitude of the T-cell response correlated with symptoms and the humoral response. In addition, SARS-CoV-2 infection significantly boosted the endemic coronavirus-specific cellular response. Overall, our data suggest discordant humoral and cellular responses, reflecting either abortive infection, cellular sensitization with rapid viral clearance or rapid antibody waning or a combination of these phenomena. Restricting epidemiologic analysis to SARS-CoV-2 serological data may underestimate rates of infection with or at least exposure to SARS-CoV-2 in children.


  • Open Access

    Oxygenation and intestinal perfusion and its association with perturbations of the early life gut microbiota composition of children with congenital heart disease

    by Hanna Renk, Ulrich Schoppmeier, Jennifer Müller, Vanessa Kuger, Felix Neunhoeffer, Christian Gille, Silke Peter

    Background: Early life gut microbiota is known to shape the immune system and has a crucial role in immune homeostasis. Only little is known about composition and dynamics of the intestinal microbiota in infants with congenital heart disease (CHD) and potential influencing factors.Methods: We evaluated the intestinal microbial composition of neonates with CHD (n = 13) compared to healthy controls (HC, n = 30). Fecal samples were analyzed by shotgun metagenomics. Different approaches of statistical modeling were applied to assess the impact of influencing factors on variation in species composition. Unsupervised hierarchical clustering of the microbial composition of neonates with CHD was used to detect associations of distinct clusters with intestinal tissue oxygenation and perfusion parameters, obtained by the “oxygen to see” (O2C) method.Results: Overall, neonates with CHD showed an intestinal core microbiota dominated by the genera Enterococcus (27%) and Staphylococcus (20%). Furthermore, a lower abundance of the genera Bacteroides (8% vs. 14%), Parabacteroides (1% vs. 3%), Bifidobacterium (4% vs. 12%), and Escherichia (8% vs. 23%) was observed in CHD compared to HCs. CHD patients that were born by vaginal delivery showed a lower fraction of the genera Bacteroides (15% vs. 21%) and Bifidobacterium (7% vs. 22%) compared to HCs and in those born by cesarean section, these genera were not found at all. In infants with CHD, we found a significant impact of oxygen saturation (SpO2) on relative abundances of the intestinal core microbiota by multivariate analysis of variance (F[8,2] = 24.9, p = 0.04). Statistical modeling suggested a large proportional shift from a microbiota dominated by the genus Streptococcus (50%) in conditions with low SpO2 towards the genus Enterococcus (61%) in conditions with high SpO2. We identified three distinct compositional microbial clusters, corresponding neonates differed significantly in intestinal blood flow and global gut perfusion.Conclusion: Early life differences in gut microbiota of CHD neonates versus HCs are possibly linked to oxygen levels. Delivery method may affect microbiota stability. However, further studies are needed to assess the effect of potential interventions including probiotics or fecal transplants on early life microbiota perturbations in neonates with CHD.


  • Open Access

    Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection

    by Maximilian Stich, Vladimir Gonçalves Magalhães, Friederike Bürger, Sven F. Garbade, Kathrin Jeltsch, Kerstin Mohr, Anneke Haddad, Roland Elling, Peter Lang, Armin Rabsteyn, et al.

    The pivotal role of the cell entry receptor ACE2 for SARS‐CoV‐2 infection is well‐established. When ACE2 is shed from cell surface into plasma as soluble ACE2 (sACE2), it can effectively neutralize SARS‐CoV‐2. This longitudinal prospective cohort study analyzed sACE2 activity in 1192 participants, aged 4 months to 81 years, 3 and 12 months after SARS‐CoV‐2 household exposure. Following SARS‐CoV‐2 exposure, participants exhibited significantly elevated sACE2 activity, irrespective of confirmed infection, with the highest levels observed in exposed children. Longitudinal analysis revealed a decline in sACE2 levels over time, reaching levels comparable to age‐ and sex‐matched pre‐pandemic controls. An increase in sACE2 activity was also confirmed in vitro in Calu‐3 (human lung) cells within hours of SARS‐CoV‐2 exposure, providing a direct link between SARS‐CoV‐2 exposure and elevated sACE2. This study, therefore, challenges the dichotomy of categorizing SARS‐CoV‐2 exposed participants as infected or not infected solely on currently established diagnostic assays. It demonstrates lasting host responses independent of B‐ and T‐cell memory and may help to keep SARS‐CoV‐2 infections in balance and contribute to successful virus clearance in children and adults lacking humoral and cellular immune responses following SARS‐CoV‐2 exposure.Trial Registration: German Registry for Clinical Studies; Identifier: D 00021521.


  • Open Access

    Development and validation of a respiratory syncytial virus multiplex immunoassay

    by Patrick Marsall, Madeleine Fandrich, Johanna Griesbaum, Manuela Harries, Berit Lange, RESPINOW Study Consortium, Stephanie Ascough, Pete Dayananda, Christopher Chiu, Jonathan Remppis, et al.

    Purpose: Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. While vaccines and monoclonal therapeutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses antibody titers toward the post-F, Nucleoprotein, and a diverse mix of G proteins. Methods: A bead-based multiplex RSV immunoassay was developed, technically validated to standard FDA bioanalytical guidelines, and clinically validated using samples from human challenge studies. RSV antibody titers were then investigated in children aged under 2 and a population-based cohort. Results: Technical and clinical validation showed outstanding performance, while methodological developments enabled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age-dependent antibody responses within population cohorts. Conclusion: Overall, the developed assay shows robust performance, is scalable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies.